Literature DB >> 8839478

Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization.

M C Truss1, S Uckert, C G Stief, M Kuczyk, U Jonas.   

Abstract

Phosphodiesterases (PDEs) are key enzymes involved in the regulation of intracellular cyclic nucleotide metabolism. The aim of the present study was to identify and to characterize the PDE isoenzymes present in the human detrusor smooth muscle. Human detrusor PDE isoenzymes were separated by Q-Sepharose anion exchange and calmodulin-agarose affinity chromatography and characterized upon their kinetic characteristics and their sensitivity to allosteric modulators and inhibitors. All five presently known PDE isoenzyme families were identified: one high-affinity, low-Km calcium/calmodulin-stimulated PDE I with a slight preference for cGMP over cAMP, one cGMP-stimulated PDE II, one cGMP-inhibited PDE III, one cAMP-specific PDE IV and one cGMP-specific PDE IV. All five known PDE isoenzyme families exist in human detrusor smooth musculature. The kinetic characteristics, together with functional in vitro studies, suggest that the PDE I may be of importance in the intracellular regulation of the human detrusor smooth muscle tone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839478     DOI: 10.1007/bf00304074

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  13 in total

Review 1.  Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.

Authors:  C D Nicholson; R A Challiss; M Shahid
Journal:  Trends Pharmacol Sci       Date:  1991-01       Impact factor: 14.819

Review 2.  The nitric oxide and cGMP signal transduction system: regulation and mechanism of action.

Authors:  H H Schmidt; S M Lohmann; U Walter
Journal:  Biochim Biophys Acta       Date:  1993-08-18

3.  Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.

Authors:  T J Torphy; L B Cieslinski
Journal:  Mol Pharmacol       Date:  1990-02       Impact factor: 4.436

Review 4.  Cyclic GMP and mechanisms of vasodilation.

Authors:  T M Lincoln
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

5.  Multiple cyclic nucleotide phosphodiesterase activities from rat brain.

Authors:  W J Thompson; M M Appleman
Journal:  Biochemistry       Date:  1971-01-19       Impact factor: 3.162

6.  Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators.

Authors:  H L Zhou; T J Torphy
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

7.  The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo.

Authors:  C G Stief; S Uckert; A J Becker; M C Truss; U Jonas
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

8.  Flavoxate, a drug with smooth muscle relaxing activity.

Authors:  R Ruffmann; A Sartani
Journal:  Drugs Exp Clin Res       Date:  1987

Review 9.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.

Authors:  M C Truss; S Uckert; C G Stief; P Schulz-Knappe; R Hess; W G Forssmann; U Jonas
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

View more
  18 in total

Review 1.  Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.

Authors:  Stefan Uckert; Christian G Stief; Margit Mayer; Udo Jonas; Petter Hedlund
Journal:  World J Urol       Date:  2005-12-06       Impact factor: 4.226

Review 2.  Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.

Authors:  Emilio Sacco; Francesco Pinto; Pierfrancesco Bassi
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-15

3.  [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

Authors:  S Uckert; K Sigl; E S Waldkirch; P Sandner; E Ulbrich; M Oelke; C G Stief; M A Kuczyk
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

4.  Constitutively active phosphodiesterase activity regulates urinary bladder smooth muscle function: critical role of KCa1.1 channel.

Authors:  Wenkuan Xin; Qiuping Cheng; Rupal P Soder; Eric S Rovner; Georgi V Petkov
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-15

5.  Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.

Authors:  S Oger; D Behr-Roussel; D Gorny; T Lebret; P Validire; X Cathelineau; L Alexandre; F Giuliano
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 6.  Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology.

Authors:  Georgi V Petkov
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-02       Impact factor: 3.619

Review 7.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 8.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

9.  Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.

Authors:  M Bertolotto; E Trincia; R Zappetti; R Bernich; G Savoca; M A Cova
Journal:  Radiol Med       Date:  2009-08-20       Impact factor: 3.469

10.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.